Sulphoevernan is a sulphated ~-1 --, 3, 1 -, 4 polyglucan (Mr 20000) with a helical structure. This compound effectively inhibits both human immunodeficiency virus type 1 (HIV-1) and type 2 infection of cells in vitro at concentrations around 0-5 ~tg/ml. Moreover, the compound completely inhibits HIV-l-induced syncytium formation at a concentration of 1 ~tg/ml. Competition experiments with 35S-labelled sulphoevernan revealed that the mannose-specific lectin from Narcissus pseudonarcissus prevented binding of sulphoevernan to HIV-1, whereas the antibody OKT4A did not reduce the amount of sulphoevernan bound to MT-2 cells. These data indicate that the non-cytotoxic polymer sulphoevernan binds to the virus rather than to the host cell. In vivo studies, using Rauscher leukaemia virus in NMRI mice, revealed that, at a daily dose of 20 mg/kg, the animals were protected against virus-induced increases in spleen weight. From these in vitro and in vivo data we conclude that sulphoevernan has potential in the treatment of acquired immunodeficiency syndrome.
Introduction
Antiretroviral chemotherapy of patients with acquired immunodeficiency syndrome with dideoxynucleosides, such as azidothymidine (AZT), does help some patients (Fischl et al., 1987) . However, the toxicity of AZT, a compound which presumably inhibits viral DNA polymerase in infected cells, is such that new strategies are needed (Cohen, 1987; Henderson & Gerberding, 1989) . One strategy is to develop substances that interfere with viral adsorption and penetration by blocking the CD4 receptor or the viral glycoprotein (Bagasra & Lischner, 1988) . It was discovered that dextran sulphate was able to block infection of cells by human immunodeficiency virus type 1 (HIV-I) (Ueno & Kuno, 1987) . Subsequently, other sulphated polysaccharides, e.g. heparin sulphate, chondroitin sulphate and polysulphated polyxylan, were found to have anti-HIV activity in vitro (Biesert et al., 1988; Baba et al., 1989) . These compounds inhibit virus adsorption and syncytium formation (Baba et al., 1988; Biesert et al., 1988) , although a direct influence of these drugs on the infectivity of the virus could not be demonstrated (Biesert et al., 1988) .
The hitherto studied sulphated polysaccharides with in vitro anti-HIV-1 activity are linear molecules. We now show that sulphoevernan, which is an unbranched ~-1 --, 3, 1 ~ 4 sulphated polyglucan (Stefanovich, 1969a) , displays a potent anti-HIV (type 1 and 2) activity in vitro. In vivo studies using the Rauscher leukaemia virus (RLV)/NMRI mouse system supported the anti-retroviral effect of sulphoevernan. The characteristic feature of this sulphopolyglucan is its helical structure and its antiviral activity, derived primarily by binding to the virus itself. Moreover, we demonstrate that a new lectin from Narcissus pseudonarcissus (NPL), which is characterized by a high specificity for (~-1,3) mannosyl residues, is equally effective against HIV infection in vitro.
Methods

Compounds.
[3sS]Methionine (1500 Ci/mmol) and chloro[3SS]sulphonic acid (40 mCi/mmol) were obtained from Amersham. The monoclonal antibody OKT4A was from Ortho Diagnostics and Nycodenz from Nyegaard. AZT was a gift of Professor W. Prusoff (Yale University, New Haven, Conn., U.S.A.).
Preparation of evernan and sulphoevernan. The polysaccharide evernan was isolated from oak lichen (Evernia prunastri L. Ach.) as described previously (Stefanovich, 1960) . This ct-polyglucan contains approximately 80~ 1--, 3 and 20~ 1~4 linkages and has an Mr ranging between 18K and 34K (Stefanovich, 1969a) .
Sulphonation of evernan was performed with chlorosulphonic acid, as described by Stefanovich (1969b) . The material obtained had an M r of 20K and the degree of substitution with the sulpho group was 1. The -6-0-sulpho group is located on the outside of the helical structure of sulphoevernan (Stefanovich, 1969a) . 3sS-labelled sulphoevernan was prepared from evernan using chloro[3SS]sulphonic acid as a radiolabelled precursor; the specific radioactivity was 1.2 mCi/mol of glucose.
Narcissus lectin. Lectin NPL was purified as described (Van Damme et al., 1988) . This lectin is specific for Man(~-l,3)Man residues (Van Damme et al., 1988) .
Virus strains. The human T-lymphotropic virus, type IIIB (HTLV-IIIB) (Popovi~ et al,. 1984 ) strain of HIV-1 and two HIV-2 strains, HIV-2sT (Kong et al., 1988) and HIV-2Ms (Kanki et al., 1988) were tested. HIV-I particles were prepared from the medium of HTLV-IIIBinfected H9 cells as described by Popovi6 et al. (1984) .
Radiolabelled virus was prepared as follows. Two week old HTLVlllB-infected H9 cells (Popovi~ et al., 1984) were incubated in medium containing 50 nCi/ml [35S]methionine for 2 days. A cell-free supernatant was obtained by low-speed centrifugation (4000 g, 10 rain, 4 °C). This was then dialysed against a 0.1 M-Tris-HC1 buffer (pH 7-4, 0.1 MNaC1, 0.001 M-EDTA) for 5 h at 4 °C, and virus particles were collected by centrifugation at 30000 r.p.m, in a Beckman Ti-45 rotor for 2 h at 4 °C. The resulting pellet was centrifuged over a 3 ml linear sucrose gradient for 24 h as described (Popovi~ et al., 1984) ; the fractions within the density range 1.18 to 1.15 g/ml were collected. The specific radioactivity varied between 1-3 × 10 -~6 and 2-9 x 10 -16 Ci/virion. The particles were counted by electron microscopy (Popovi6 et al., 1984) . A second purification procedure, the Nycodenz gradient centrifugation technique, was applied to prepare the virions (Vilmer et al., 1984) . After this procedure, the specific activity of the virus preparation was found to be identical to that obtained by sucrose gradient centrifugation. This is one indication that no cellular membranes had cosedimented with the virus particles.
Cells and virus infection. The human T cell lines MT-2 (Harada et al., 1985) , CEM (Nara & Fischinger, 1988) , ATH8 (Mitsuya & Broder, 1986) and H9 (Popovi6 et al., 1984) , the human monocyte line U937 (Ezekovitz et al., 1989 ) and the somatic cell hybrid culture between CEM and the B cell line 174 (Kong et al., 1988) were grown in RPMI 1640 medium supplemented with 15 % (v/v) foetal calf serum. Cultures were maintained at 37 °C in a humidified atmosphere at 5 ~ CO2 in air.
HIV-1 infection. Cells were routinely seeded at a concentration of 1 x l0 s cells/ml and HIV-1 virus was added to give an m.o.i, of 3 TCIDso per MT-2 cell and 12 TCIDs0 per CEM or U937 cell. The cells were incubated in the presence or absence of the test compounds for 7 days. During that time, the uninfected MT2 cells underwent 2-91 doubling steps, CEM cells 2-14 doublings and U937 cells 1.93 doublings. The infected cells underwent the following doubling steps: MT-2/HIV-1, 0.09, CEM/HIV-1, 0.04, and U937/HIV-1, 0.08.
Except where otherwise mentioned, clarified conditioned HIV-1 culture fluid was pretreated (30 rain at 36 °C) with the different compounds and then added to the cells to provide the indicated compound and virus concentrations. The virus preparation was preincubated together with the compound in a volume of 100 ~tl, resulting in a 10-fold higher concentration than that finally present in the cell culture experiment.
HIV-2 infection. HIV-2sr-producing CEMx174 cells and HIV-2~as-producing U937 cells were irradiated with 10000 rads and then cocultivated at a density of 4 x 10 ~ cells/ml, final assay volume, with 2 × 105 ATH8 ceils. After 7 days incubation, only the ATH8 cells were alive and their densities were estimated. The test compounds were added to the irradiated cells 30 min prior to the addition of the ATH8 cells. In the uninfected control cultures, the ATH8 cells underwent 2.01 doubling steps during the 7 day incubation.
Evaluation. Cell concentrations were routinely evaluated using the XTT colorimetric assay system (Scudiero et al., 1988) , followed by evaluation with an ELISA reader (Bio-Rad, model 3550, equipped with the program NCIMR IIIB). To standardize growth curves, the cells were counted electronically (Cytocomp Counter; model Michaelis). The number of doubling steps was determined as described (Miiller et al., 1975) .
The 50~ cytoprotective concentration (IC5o) represents that concentration at which growth of HIV-infected cells reached 50~ of the growth rate of the uninfected cells during an incubation period of 7 days. The 50~ cytotoxic concentration (TCs0) represents that concentration at which the growth rate of the infected cells was reduced by 50~; this value is usually similar to the TCso of uninfected cells. The 50~ values were estimated by logit regression (Sachs, 1984) . The antiviral index (AI) is calculated from the ratio TCso:IC5o.
To test for virus release after the 7 days incubation period, cells were removed by centrifugation and the supernatant was assayed for reverse transcriptase (RT) activity (Schr6der et al., 1989) . The percentage of cells expressing the p24 gag proteins of HIV-1 was determined by indirect immunofluorescence microscopy, with the use of mouse monoclonal antibodies to HIV-1 p24. The positive cells were visualized by treatment with fluorescein-labelled goat anti-mouse IgG (Poiesz et al., 1980) ; the reactivity of the antibodies with HIV-1 infected cells was in the range of 30 to 40~.
Syncytium induction assay.
This assay was performed as described (Matthews et al., 1987) . A total of I x l0 s HIV-l-infected H9 cells were mixed with 1 × 105 uninfected Jurkat cells in a final volume of 100 ~tl, either in the presence or the absence of the compounds. Syncytium formation (defined as > 4 nuclei within a common cell membrane) was semiquantitatively scored 5 and 24 h later (Lifson et al., 1986) : -, no syncytia; 1+; rare small syncytia; 2+, multiple moderately sized syncytia; 3+, large syncytia in most, but not all microscope fields (magnification 400×); 4+, numerous large syncytia in all fields examined.
Virus-cellbindingstudies. MT-2 cells (1 x 105) were suspended in 1 ml of binding assay buffer [20 m~-sodium phosphate, 1 mM-CaC12, 130 mM-NaC1, 2 ~ w/v bovine serum albumin (M/iller et al., 1982) ]. Then, 20 tal of labelled virus [approximately 25 × 104 &p.m./assay (final)] was added and incubated for 0 to 60 min at 37 °C in 5 ~ CO2. The cells were subsequently washed by centrifugation (2000 g, 10 min, 4 °C) and their radioactivity counted. Where indicated, the virus preparation (20 vtl) was preincubated for 1 h at 4 °C with a 10 ~tl solution of sulphoevernan, evernan or NPL and then added to the cells. Protein concentration. This was determined as described (Lowry et al., 1951) , using bovine serum albumin as a standard.
Statistics. For the statistical evaluation, Student's t-test was applied (Sachs, 1984) .
Results
Anti-HIV activity of sulphoevernan and NPL
The compounds evernan, sulphoevernan, a sulphated polyglucan (Fig. 1 ), and NPL were tested for anti-HIV activity by the cytoprotection assay; cell density was determined by the XTT tetrazolium/formazan assay. As shown in Table 1 cytoprotective activity both on HIV-1-and HIV-2-infected cells. The dose-response curves show that the compound was not at all toxic to the cells up to the maximum concentration tested of 100 ~tg/ml. The IC5o in the assays with HIV-l-infected cells was determined to be 0-32 ~tg/ml (equivalent to 16 nM) and for HIV-2-infected cells 0.38 ~tg/ml (equivalent to 19 nM). In both virus-infected systems, sulphoevernan at concentrations above 1 ~tg/ml gave a 100~ cytoprotective effect. In addition to U937 monocytes, we tested the human T cell lines MT-2 and CEM in order to determine whether the anti-HIV-1 cytoprotective effect was dependent on the host cell line. As summarized in Table 1 , the antiviral index for sulphoevernan varied from > 192 to > 312. Although on a weight/concentration basis it was much less effective, on a molar basis sulphoevernan [IC50 0-52 ~g/ml (equivalent to 26 nM)] was as effective as AZT [ICso 0-008 ~tg/ml (equivalent to 30 riM)] in the MT-2/HIV-1 system. The non-sulphonated evernan was without any effect, whereas the mannose-specific NPL displayed a considerable anti-HIV-I cytoprotective effect, with an AI between >14 and >46.
The anti-HIV-2 effect of sulphoevernan was equally strong in both the CEMx 174/HIV-2sT and the U937/HIV-2MS systems, where the AI was determined to be >137 and >263, respectively. Moreover, this compound is characterized by an IC5o value of 0.73 ~tg/ml --* Syncytia were scored 5 and 24 h after addition of uninfected Jurkat cells to HIV-l-producing H9 cells. The compounds were added at the beginning of the co-incubation period and remained in the assays until the evaluation.
(equivalent to 37 riM), which is again superior to the ICs0 value for AZT [0.023 ~tg/ml (equivalent to 86 nM)] under the in vitro conditions (CEM x 174/HIV-2sT) used. In addition, sulphoevernan displayed no cytotoxic effects up to 100 ~tg/ml, whereas AZT caused a 50~ cytotoxic effect at concentrations around 9 gg/ml (Table 1) . For comparison, we have included in the tables the inhibitory activity of AZT against HIV-1 and HIV-2.
To demonstrate that the cytoprotective effect displayed by sulphoevernan was due to a direct anti-HIV effect, the reduction in the expression of HIV-1 protein p24 as well as the reduction in virus particles (measured by the determination of RT level) was determined in the CEM/HIV-1 system (data not shown). At a concentration of 0.5 I.tg/ml of sulphoevernan, a 49~ inhibition of HIV-1 p24 expression and 43 ~ reduction of the RT level in the culture fluid was detectable. At 1 gg/ml, both the inhibition and the reduction were complete.
Inhibition of syncytium formation by sulphoevernan and NPL
Addition of sulphoevernan or NPL during the coincubation period of Jurkat cells with HIV-l-producing H9 cells strongly inhibited syncytium formation (Table  2) . At a concentration of 1 gg/ml of sulphoevernan or 3 ~g/ml of NPL no syncytium formation could be measured. Again, evernan gave no protection.
Inhibition of HIV-1 binding to MT-2 cells by sulphoevernan
Addition of both sulphoevernan (3 gg/ml) and NPL (20 Ixg/ml) almost completely abolished the binding of HIV-1 particles to MT-2 cells (Fig. 2) , whereas evernan had no effect on this system. Furthermore, antibody OKT4A, [35S]Methionine-labelled HIV-1 was incubated with MT-2 cells either in the absence of any additional compound (O) or in the presence of 3 gg/ml of sulpboevernan (O), 100 gg/ml of evernan (f-]), 20 ~tg/ml of NPL ( × ), or 100 gg/ml of the monoclonal antibody OKT4A (I). The samples were taken after 0 to 60 rain and radioactivity bound to MT-2 cells was determined.
which prevents the binding of HIV to CD4 receptors on cells (Bagasra & Lischner, 1988) , also inhibited virus binding; 1-5 x 103 virus particles were estimated to be bound to each cell.
Binding of sulphoevernan to HIV-1 particles
To determine whether sulphoevernan protects MT-2 cells against HIV-1 infection by binding to receptors on the virus particles, competition experiments with NPL and antibody OKT4A were performed. The rationale for selecting these two tools was that NPL, with its high specificity for Man(~-l,3)Man residues, would mask the carbohydrate structures of the virus gpl20 (Geyer et al., 1988; Mizuochi et al., 1988) and OKT4A would mask the CD4 virus-binding sites on cells (Bagasra & Lischner, 1988) .
The experiments revealed that [35S]sulphoevernan bound only to a small extent to both virus particles and MT-2 cells in the absence of Ca 2+ (Table 3) . Addition of 1 mM-CaC12 strongly enhanced the affinity of sulphoevernan for HIV-1; 120 d.p.m, of [3SS]sulphoevernan was determined to bind to virus particles in the absence of Ca 2+ and 1730 d.p.m, in its presence. In a control experiment it was established that addition of a 20-fold surplus of unlabelled sulphoevernan (8 ~tg/200 gl) to the labelled compound (0.4 gg/200 ~tl) reduced the amount of radioactivity bound to the virus by 95Voo (not shown). Preincubation of the virus particles with NPL prevented binding of sulphoevernan to the virus (Table 3) ; only 8 ~o of the radioactivity was found to be associated with the virus compared to the amount measured in the absence of NPL. Sulphoevernan also bound to uninfected MT-2 cells in the presence of Ca2+; however the extent of binding was not reduced when the cells were preincubated with the antibody. The extent of binding of sulphoevernan was not significantly altered when the studies were performed with HIV-l-infected cells which are known to express the viral glycoprotein gpl20 (Garry, 1989) . These data suggest that, in the presence of Ca 2÷ ions, sulphoevernan binds predominantly to the cell-binding receptor of the virus (gpl20) and, although it also binds to the cells, not to the CD4 virus-binding receptor sites.
Antiretroviral activity of sulphoevernan in vivo
To test for antiretroviral activity in vivo, the RLV/NMRI mouse system was used. As summarized in Table 4 , sulphoevernan administered subcutaneously, beginning 1 day after RLV inoculation and then given daily for 8 days at a dose of 20 mg/kg, completely prevented increases in spleen weight. The lower dose of 5 mg/kg suppressed the weight increase by 95 %. If administration of the compound was started at day 5, the antiretroviral activity was complete at a daily dose of 20 mg/kg and already significant (P < 0-01) at a daily dose of 5 mg/kg,
Discussion
Like dextran sulphate (Mitsuya et al., 1988; Baba et al., 1988) and polysulphated polyxylan (Biesert et al., 1988) , sulphoevernan displays potent anti-HIV activity in vitro. The ant±viral effect, measured on the basis of 50% cytoprotection, was observed at a concentration as low as 0.3 gg/ml for both HIV-1 and HIV-2 strains. Hence sulphoevernan displays a higher ant±viral potency than dextran sulphate (EDs0 9.1 gg/ml) (Baba et al., 1988) . In contrast to dextran sulphate, sulphoevernan completely inhibits syncytium formation at a concentration of 1 rig/ml. Moreover, sulphoevernan is 20 times more potent than the polysulphated polyxylan (minimum inhibitory concentration 20 gg/ml) in this assay system (Biesert et al., 1988) . At present we attribute this effect to the helical structure of sulphoevernan which might facilitate its interaction with viral gpl20 (see below). This polysaccharide was not toxic to cells, a property which is shared with other sulphated polysaccharides (Mitsuya et al., 1988; Baba et al., 1988; Biesert et al., 1988) . We have addressed the question of which structure sulphoevernan binds to, thereby preventing HIV-infection. H IV-1 gp 120 and the cellular CD4 are glycoproteins that are considered to interact with one other and to allow the binding of the virus to CD4 + cells (Klatzmann et aL, 1984; Dalgleish e! al., 1984) . Both the protein backbone and oligosaccharide side-chains of gpl20 contribute to its ability to bind to CD4 (Putney et al., 1986; Fennie & Lasky, 1989) . The carbohydrate structures of gp t 20 can be subdivided into high-mannose and complex types; the latter glycans terminate with sialic acid residues (Geyer et al., 1988; Mizuochi et al., 1988) . In a previous study, it was shown that Gerardia savaglia lectin, which specifically recognizes (~-l,2)-mannosyl residues, prevents binding of HIV-1 to H9 cells via complex formation with gpl20 (Miiller et al., 1988a, b) . We now show that NPL, with its high specificity for (0t-1,3)-mannosyl residues (Van Damme et al., 1988) , also prevents HIV-1 and HIV-2 infection of cells in vitro. Both the (~-1,2)-and the (~-1,3)-mannose residues reside in oligomannosidic side-chains of the high-mannose type (Geyer et al., 1988) . Using NPL and OKT4A antibodies, we also demonstrated that binding of sulphoevernan to HIV is prevented by NPL whereas the antibodies displayed no effect on the interaction between sulphoevernan and cells.
This finding indicates that sulphoevernan inhibits HIV infection by binding to the virus, provided that Ca 2+ ions are present. In the absence of Ca 2÷ ions the binding of sulphoevernan was negligible. Hence, we suppose that Ca 2÷ allows binding of sulphoevernan to the sialic acid residues of complex type carbohydrates of gpl20, a binding which is both feasible and strong (Wang, 1986) . At present we cannot decide to which molecule on the cell surface the virus binds via Ca 2+ ions.
The results presented here, namely that sulphoevernan exhibits potent anti-HIV activity, might be of practical significance in view of earlier findings which revealed a series of important biopharmacological properties of sulphoevernan, e.g. complex formation with a human fllipoprotein and with histamine, increase of prothrombin time and enhancement of hydrolysis of triolein (Stefanovich, 1969a) . Moreover, sulphoevernan also inhibits the esterification of cholesterol (Stefanovich, 1969b) and decreases experimental aortic arteriosclerosis in rabbits (Stefanovich et al., 1970) . A more important aspect, in the context of the anti-HIV effect of sulphoevernan in vitro, was our finding that, in the in vivo retrovirus model system, RLV-infected mice, sulphoevernan protected the animals against virus-induced disseminated lymphoma. At a daily dose of 20 mg/kg, sulphoevernan completely suppressed elevation of spleen weight.
